New drug duo aims to shrink tough head and neck tumors
NCT ID NCT03650764
Summary
This study is testing whether combining two existing drugs, ramucirumab and pembrolizumab, works better than pembrolizumab alone for advanced head and neck cancer that has returned or spread. The first part of the study aims to find a safe dose for the combination. The second part will see how well the combination shrinks tumors in patients who have not yet received other drug treatments for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.